vs
雅培（ABT）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
雅培的季度营收约是登士柏西诺德的11.9倍（$11.5B vs $961.0M）。雅培净利率更高（15.5% vs -15.2%，领先30.7%）。登士柏西诺德同比增速更快（6.2% vs 4.4%）。雅培自由现金流更多（$2.6B vs $60.0M）。过去两年雅培的营收复合增速更高（7.2% vs 0.4%）
雅培是总部位于美国伊利诺伊州雅培园的跨国医疗健康企业，业务覆盖美国境外市场药品销售、诊断产品、营养产品及医疗器械等板块，在全球医疗健康领域拥有较高的行业知名度与广泛的市场覆盖。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
ABT vs XRAY — 直观对比
营收规模更大
ABT
是对方的11.9倍
$961.0M
营收增速更快
XRAY
高出1.8%
4.4%
净利率更高
ABT
高出30.7%
-15.2%
自由现金流更多
ABT
多$2.6B
$60.0M
两年增速更快
ABT
近两年复合增速
0.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $11.5B | $961.0M |
| 净利润 | $1.8B | $-146.0M |
| 毛利率 | 57.0% | 46.1% |
| 营业利润率 | 19.6% | -14.5% |
| 净利率 | 15.5% | -15.2% |
| 营收同比 | 4.4% | 6.2% |
| 净利润同比 | -80.8% | 66.0% |
| 每股收益（稀释后） | $1.01 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTXRAY
| Q4 25 | $11.5B | $961.0M | ||
| Q3 25 | $11.4B | $904.0M | ||
| Q2 25 | $11.1B | $936.0M | ||
| Q1 25 | $10.4B | $879.0M | ||
| Q4 24 | $11.0B | $905.0M | ||
| Q3 24 | $10.6B | $951.0M | ||
| Q2 24 | $10.4B | $984.0M | ||
| Q1 24 | $10.0B | $953.0M |
净利润ABTXRAY
| Q4 25 | $1.8B | $-146.0M | ||
| Q3 25 | $1.6B | $-427.0M | ||
| Q2 25 | $1.8B | $-45.0M | ||
| Q1 25 | $1.3B | $20.0M | ||
| Q4 24 | $9.2B | $-430.0M | ||
| Q3 24 | $1.6B | $-494.0M | ||
| Q2 24 | $1.3B | $-4.0M | ||
| Q1 24 | $1.2B | $18.0M |
毛利率ABTXRAY
| Q4 25 | 57.0% | 46.1% | ||
| Q3 25 | 55.4% | 48.8% | ||
| Q2 25 | 56.4% | 52.4% | ||
| Q1 25 | 56.9% | 53.0% | ||
| Q4 24 | 55.0% | 49.3% | ||
| Q3 24 | 55.8% | 52.1% | ||
| Q2 24 | 55.6% | 51.9% | ||
| Q1 24 | 55.2% | 53.1% |
营业利润率ABTXRAY
| Q4 25 | 19.6% | -14.5% | ||
| Q3 25 | 18.1% | -24.1% | ||
| Q2 25 | 18.4% | -13.7% | ||
| Q1 25 | 16.3% | 7.2% | ||
| Q4 24 | 17.4% | -56.2% | ||
| Q3 24 | 17.5% | -48.6% | ||
| Q2 24 | 16.1% | 5.1% | ||
| Q1 24 | 13.9% | 4.4% |
净利率ABTXRAY
| Q4 25 | 15.5% | -15.2% | ||
| Q3 25 | 14.5% | -47.2% | ||
| Q2 25 | 16.0% | -4.8% | ||
| Q1 25 | 12.8% | 2.3% | ||
| Q4 24 | 84.1% | -47.5% | ||
| Q3 24 | 15.5% | -51.9% | ||
| Q2 24 | 12.5% | -0.4% | ||
| Q1 24 | 12.3% | 1.9% |
每股收益（稀释后）ABTXRAY
| Q4 25 | $1.01 | $-0.74 | ||
| Q3 25 | $0.94 | $-2.14 | ||
| Q2 25 | $1.01 | $-0.22 | ||
| Q1 25 | $0.76 | $0.10 | ||
| Q4 24 | $5.26 | $-2.09 | ||
| Q3 24 | $0.94 | $-2.46 | ||
| Q2 24 | $0.74 | $-0.02 | ||
| Q1 24 | $0.70 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.9B | $326.0M |
| 总债务越低越好 | $12.9B | $2.3B |
| 股东权益账面价值 | $52.1B | $1.3B |
| 总资产 | $86.7B | $5.4B |
| 负债/权益比越低杠杆越低 | 0.25× | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资ABTXRAY
| Q4 25 | $8.9B | $326.0M | ||
| Q3 25 | $7.7B | $363.0M | ||
| Q2 25 | $7.3B | $359.0M | ||
| Q1 25 | $6.8B | $398.0M | ||
| Q4 24 | $8.0B | $272.0M | ||
| Q3 24 | $7.8B | $296.0M | ||
| Q2 24 | $7.2B | $279.0M | ||
| Q1 24 | $6.7B | $291.0M |
总债务ABTXRAY
| Q4 25 | $12.9B | $2.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $14.1B | $1.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ABTXRAY
| Q4 25 | $52.1B | $1.3B | ||
| Q3 25 | $51.0B | $1.5B | ||
| Q2 25 | $50.6B | $2.0B | ||
| Q1 25 | $48.8B | $2.0B | ||
| Q4 24 | $47.7B | $1.9B | ||
| Q3 24 | $39.8B | $2.5B | ||
| Q2 24 | $39.3B | $3.1B | ||
| Q1 24 | $38.8B | $3.3B |
总资产ABTXRAY
| Q4 25 | $86.7B | $5.4B | ||
| Q3 25 | $84.2B | $5.7B | ||
| Q2 25 | $84.0B | $6.1B | ||
| Q1 25 | $81.4B | $6.0B | ||
| Q4 24 | $81.4B | $5.8B | ||
| Q3 24 | $74.4B | $6.6B | ||
| Q2 24 | $73.0B | $6.9B | ||
| Q1 24 | $72.5B | $7.1B |
负债/权益比ABTXRAY
| Q4 25 | 0.25× | 1.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.30× | 0.90× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $101.0M |
| 自由现金流经营现金流 - 资本支出 | $2.6B | $60.0M |
| 自由现金流率自由现金流/营收 | 22.9% | 6.2% |
| 资本支出强度资本支出/营收 | 6.0% | 4.3% |
| 现金转化率经营现金流/净利润 | 1.87× | — |
| 过去12个月自由现金流最近4个季度 | $7.4B | $104.0M |
8季度趋势，按日历期对齐
经营现金流ABTXRAY
| Q4 25 | $3.3B | $101.0M | ||
| Q3 25 | $2.8B | $79.0M | ||
| Q2 25 | $2.0B | $48.0M | ||
| Q1 25 | $1.4B | $7.0M | ||
| Q4 24 | $2.9B | $87.0M | ||
| Q3 24 | $2.7B | $141.0M | ||
| Q2 24 | $2.0B | $208.0M | ||
| Q1 24 | $1.0B | $25.0M |
自由现金流ABTXRAY
| Q4 25 | $2.6B | $60.0M | ||
| Q3 25 | $2.3B | $40.0M | ||
| Q2 25 | $1.5B | $16.0M | ||
| Q1 25 | $933.0M | $-12.0M | ||
| Q4 24 | $2.1B | $36.0M | ||
| Q3 24 | $2.1B | $98.0M | ||
| Q2 24 | $1.4B | $156.0M | ||
| Q1 24 | $627.0M | $-9.0M |
自由现金流率ABTXRAY
| Q4 25 | 22.9% | 6.2% | ||
| Q3 25 | 20.2% | 4.4% | ||
| Q2 25 | 13.9% | 1.7% | ||
| Q1 25 | 9.0% | -1.4% | ||
| Q4 24 | 19.6% | 4.0% | ||
| Q3 24 | 20.2% | 10.3% | ||
| Q2 24 | 13.8% | 15.9% | ||
| Q1 24 | 6.3% | -0.9% |
资本支出强度ABTXRAY
| Q4 25 | 6.0% | 4.3% | ||
| Q3 25 | 4.4% | 4.3% | ||
| Q2 25 | 4.5% | 3.4% | ||
| Q1 25 | 4.7% | 2.2% | ||
| Q4 24 | 6.6% | 5.6% | ||
| Q3 24 | 5.2% | 4.5% | ||
| Q2 24 | 5.1% | 5.3% | ||
| Q1 24 | 4.0% | 3.6% |
现金转化率ABTXRAY
| Q4 25 | 1.87× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.07× | 0.35× | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 1.51× | — | ||
| Q1 24 | 0.84× | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABT
暂无分部数据
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
